Relative Replicative Fitness of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide (T-20)

Journal of Virology

Volumn 78, Issue 9, 2004, Pages 4628-4637

  Lu, Jing ^a   Sista, Prakash ^b,c   Giguel, Françoise ^a   Greenberg, Michael ^b   Kuritzkes, Daniel R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Trimeris Inc   (United States)

^c BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASSAY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; ENVELOPE GENE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR CLONING; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEQUENCE TAGGED SITE; SITE DIRECTED MUTAGENESIS; TREATMENT FAILURE; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS VIRULENCE;

CELL LINE; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PEPTIDE FRAGMENTS; RECOMBINATION, GENETIC; VIRUS REPLICATION;

EID: 3042799046     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.9.4628-4637.2004     Document Type: Article

References (22)

1. Bozzette, S. A., J. A. McCutchan, S. A. Spector, B. Wright, and D. D. Richman. 1993. A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. J. Infect. Dis. 168:1374-1379.
2. Chan, D., D. Fass, J. Berger, and P. Kim. 1997. Core structure of gp41 from the envelope glycoprotein. Cell 89:263-273.
3. Deeks, S. G., T. Wrin, T. Liegler, R. Hoh, M. Hayden, J. D. Barbour, N. S. Hellmann, C. J. Petropoulos, J. M. McCune, M. Hellerstein, and R. M. Grant. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344:472-480.
4. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512-525.
5. Furuta, R. A., C. T. Wild, Y. Weng, and C. D. Weiss. 2002. Capture of an early fusion-active conformation of HIV-1 gp41. Nat. Struct. Biol. 5:276-279.
6. Japour, A. J., D. L. Mayers, V. A. Johnson, D. R. Kuritzkes, L. A. Beckett, J. M. Arduino, J. Lane, R. J. Black, P. S. Reichelderfer, R. T. D'Aquila, C. S. Crumpacker, et al. 1993. Standardized peripheral blood mononuclear cell culture assay for the determination of drug susceptibilities of clinical human immunodeficiency virus 1 isolates. Antimicrob. Agents Chemother. 37:1095-1101.
7. Kilby, J. M., S. Hopkins, T. Venetta, B. DiMassimo, G. Cloud, J. Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Matthews, M. R. Johnson, M. A. Nowak, G. M. Shaw, and M. S. Saag. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1302-1307.
8. Kimpton, J., and M. Emerman. 1992. Detection of replication competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J. Virol. 66:2232-2239.
9. Kosalaraksa, P., M. F. Kavlick, V. Maroun, R. Le, and H. Mitsuya. 1999. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay. J. Virol. 73:5356-5363.
10. Lalezari, J., J. Eron, M. Carlson, C. Cohen, E. DeJesus, R. Arduino, J. Gallant, P. Volberding, R. Murphy, F. Valentine, E. Nelson, P. Sista, A. Dusek, and J. Kilby. 2003. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 17:691-698.
11. Lalezari, J., K. Henry, M. O'Hearn, J. Montaner, P. Piliero, B. Trottier, S. Walmsley, C. Cohen, D. Kuritzkes, J. J. Eron, J. Chung, R. DeMasi, L. Donatacci, C. Drobnes, J. Delehanty, M. Salgo, et al. 2003. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348:2175-2185.
12. Lu, J., and D. R. Kuritzkes. 2001. A novel recombinant marker virus assay for comparing the relative fitness of HIV-1 reverse transcriptase variants. J. Acquir. Immune Defic. Syndr. 27:7-13.
13. Martinez-Picado, J., A. V. Savara, L. Sutton, and R. T. D'Aquila. 1999. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 73:3744-3752.
14. Melikyan G. B., R. M. Markosyan, H. Hemmati, M. K. Delmedico, D. Lambert, and F. S. Cohen. 2000. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J. Cell Biol. 151:413-423.
15. Nijhuis, M., R. Schuurman, D. de Jong, J. Erickson, E. Gustchina, J. Albert, P. Schipper, S. Gulnik, and C. A. B. Boucher. 1999. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13:2349-2360.
16. Reeves, J., S. Gallo, N. Ahmad, J. Miamidian, P. E. Harvey, M. Sharron, S. Pohlmann, J. N. Sfakianos, C. A. Derdeyn, R. Blumenthal, E. Hunter, and R. W. Doms. 2002. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. USA 99:16249-16254.
17. Rimsky, L. T., D. C. Shugars, and T. J. Matthews. 1998. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72:986-993.
18. Sharma, P. L., and C. Crumpacker. 1999. Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val; a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Va. J. Virol. 73:8448-8456.
19. Wakefield, J. K., S. A. Jablonski, and C. D. Morrow. 1992. In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome. J. Virol. 66:6806-6812.
20. Wei, X., J. M. Decker, H. Lfu, Z. Zhang, R. Arani, J. M. Kilby, M. Saag, S. Wu, and J. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
21. Wild, C. T., D. Shugars, T. Greenwell, C. McDanal, and T. Matthews. 1994. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA 91:9770-9774.
22. Wild, C. T., C. Oas, D. McDanal, D. Bolognesi, and T. Matthews. 1992. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. USA 89:10537-10541.